TTNP Archives - BioTuesdays

Executive Moves

Titan Pharma names new CEO, expands board

Titan Pharmaceuticals (NASDAQ:TTNP) appointed Activist Investing’s David Lazar as interim chairman and CEO, with a mandate to lead Titan’s continuing review of strategic alternatives. He succeeds Marc Rubin, M.D...

August 16, 2022

Developments

FDA clears Titan Pharma IND for nalmefene implant

The FDA has cleared Titan Pharmaceuticals’ (NASDAQ:TTNP) investigational new drug application for a Phase 1 study of its six-month or longer subdermal formulation of nalmefene, an opioid antagonist, intended for the...

July 5, 2022

Developments

Titan Pharmaceuticals to explore strategic alternatives

Titan Pharmaceuticals (NASDAQ:TTNP) engaged Maxim Group as its exclusive financial advisor to explore and evaluate strategic alternatives to enhance shareholder value. Potential strategic alternatives that may be...

December 21, 2021

Feature

Titan Pharmaceuticals, UW treating chronic itch with ProNeura implant

As a research assistant professor at the Department of Pharmacology at the University of Washington, Dr. Ben Land, Ph.D. is broadly interested in how cannabinoids and opioids mediate pain and reward. But in a...

November 9, 2021

Developments

Sustained anti-pruritic effect of Titan’s TP-2021 implant featured at Neuroscience conference

In a presentation at the Society for Neuroscience 2021 meeting, Ben Land, Ph.D., research assistant professor at the University of Washington’s Department of Pharmacology, reported additional positive data from an...

November 8, 2021

Developments

Titan Pharma receives funding from Gates Foundation for combination HIV therapeutic and contraceptive implant for women in developing countries

Titan Pharmaceuticals (NASDAQ:TTNP) has received funding from the Bill & Melinda Gates Foundation to support its ability to deliver a human immunodeficiency virus (HIV) preventative therapeutic and a contraceptive...

October 25, 2021

Developments

Titan Pharma, MUSC Foundation in research, option license agreement

Titan Pharmaceuticals (NASDAQ:TTNP) entered into a research and option license agreement with the MUSC Foundation for Research Development (MUSC FRD) and will conduct certain research, evaluation, proof-of-concept...

October 12, 2021

Developments

FDA clears Vifor, Cara pruritus injection associated with CKD

The FDA approved an NDA from Vifor Pharma and Cara Therapeutics (NASDAQ:CARA) for their KORSUVA injection for the treatment of moderate-to-severe pruritus (itch) associated with chronic kidney disease in adults...

August 24, 2021

Developments

Titan posts positive results in first studies of TP-2021 implant in chronic pruritus

Titan Pharmaceuticals (NASDAQ:TTNP) reported that an in vivo study of its ProNeura-based human kappa-opioid receptor agonist, TP-2021, implant in an established itch-induced mouse model has demonstrated the...

June 23, 2021

Markets

Maxim ups Titan Pharma to buy from hold; PT $11

Maxim Group upgraded Titan Pharmaceuticals (NASDAQ:TTNP) to “buy” from “hold” with a new price target of $11, citing multiple strategy, management, cap-structure and financing changes at Titan, which should position the...

February 18, 2021

Tag - TTNP

Titan Pharma names new CEO, expands board

FDA clears Titan Pharma IND for nalmefene implant

Titan Pharmaceuticals to explore strategic alternatives

Titan Pharmaceuticals, UW treating chronic itch with ProNeura implant

Sustained anti-pruritic effect of Titan’s TP-2021 implant featured at Neuroscience conference

Titan Pharma receives funding from Gates Foundation for combination HIV therapeutic and contraceptive implant for women in developing countries

Titan Pharma, MUSC Foundation in research, option license agreement

FDA clears Vifor, Cara pruritus injection associated with CKD

Titan posts positive results in first studies of TP-2021 implant in chronic pruritus

Maxim ups Titan Pharma to buy from hold; PT $11

General

More